Serious adverse event following immunization and thromboembolic events associated with COVID19 vaccination: An analysis of nationwide causality assessment from India

• Published in: Indian heart journal Vol. 75; no. 2; pp. 139 - 144
• Main Authors: Gandhi, Aravind P., Venkatesh, U., Murali, Naveen
• Format: Journal Article
• Language: English
• Published: India Elsevier, a division of RELX India, Pvt. Ltd 01.03.2023; Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd; Elsevier
• Subjects: Adverse Drug Reaction Reporting Systems; Adverse events following immunization; ChAdOx1 nCoV-19; COVID-19 - epidemiology; COVID-19 - prevention & control; COVID-19 vaccine; COVID-19 Vaccines - adverse effects; Deaths; Female; Humans; Immunization - adverse effects; India; India - epidemiology; Pandemics; Thromboembolic events; Vaccination - adverse effects; Vaccines - adverse effects; India; COVID-19 vaccine; Deaths; Thromboembolic events; Adverse events following immunization; India
• ISSN: 0019-4832; 2213-3763
• DOI: 10.1016/j.ihj.2023.02.004

Vaccines against the COVID-19 pandemic were introduced in late 2020. The present study has been conducted to study the serious Adverse Events Following Immunization (AEFIs) reported for COVID-19 vaccines from India. Secondary data analysis of the causality assessment reports for the 1112 serious AEFIs published by the Ministry of Health & Family Welfare, Government of India, was conducted. For the current analysis, all the reports published till 29.03.2022 were included. The primary outcome variables analyzed were the consistent causal association and the thromboembolic events. The majority of the serious AEFIs assessed were either coincidental (578, 52%) or vaccine product related (218, 19.6%). All the serious AEFIs were reported among the Covishield (992, 89.2%) and COVAXIN (120, 10.8%) vaccines. Among these, 401 (36.1%) were deaths, and 711 (63.9%) were hospitalized and recovered. On adjusted analysis, females, the younger age group and non-fatal AEFIs showed a statistically significant consistent causal association with COVID-19 vaccination. Thromboembolic events were reported among 209 (18.8%) of the analyzed participants, with a significant association with higher age and case fatality rate. Deaths reported under serious AEFIs were found to have a relatively lower consistent causal relationship with the COVID-19 vaccines than the recovered hospitalizations in India. No consistent causal association was found between the thromboembolic events and the type of COVID-19 vaccine administered in India.